Dietary soy-derived isoflavone phytoestrogens. Could they have a role in coronary heart disease prevention?
Soy protein-containing foods are a rich source of isoflavone phytoestrogens, such as genistein and daidzein. There is great interest in these substances, as lower rates of chronic diseases, including coronary heart disease, have been associated with high dietary intake of soy-containing foods. Soy phytoestrogens bind weakly to estrogen receptors, and some bind more strongly to estrogen receptor-beta compared with estrogen receptor-alpha. A meta-analysis has indicated that isoflavone phytoestrogens lowered plasma cholesterol concentrations in subjects with initially elevated levels, but had little effect in subjects with normal cholesterol concentrations. These substances reportedly may also have beneficial effects on arterial endothelial function. In addition to these potentially antiatherogenic effects, many laboratories are investigating other possible mechanisms, including antioxidative and antiproliferative properties of these substances. We have shown that dietary supplementation with soy-derived isoflavones reduced the in vitro oxidation susceptibility of low-density lipoprotein (LDL). To further explore this phenomenon, we incorporated genistein and daidzein into LDL molecules in vitro with the aid of an artificial transfer system. However, it was necessary to convert the isoflavone molecules to fat-soluble derivatives, fatty acid esters (analogous to esterified endogenous estrogens, which are known to occur in vivo), to achieve significant incorporation. The LDLs containing esterified isoflavones were shown to be less susceptible to oxidation in vitro than native LDL. We also employed U937 cell cultures for investigating the effects of isoflavone-containing LDLs on cell proliferation. Some of these LDLs exhibited antiproliferative effects in cultured U937 cells. In summary, lipophilic phytoestrogen derivatives could be incorporated into LDLs, increasing their oxidation resistance and antiproliferative efficacy ex vivo, both of which are, in theory, antiatherogenic effects. Further studies are needed to assess to what extent analogous effects could be produced in vivo and whether such substances have a role in hormone replacement and coronary heart disease prevention in postmenopausal women.
Tikkanen
M J
MJ
Department of Medicine, Helsinki University Central Hospital, 00290 Helsinki, Finland. matti.j.tikkanen@helsinki.fi
Adlercreutz
H
H
D000975:Antioxidants / Q000627:therapeutic use; D003327:Coronary Disease / Q000178:diet therapy / Q000517:prevention & control*; D004032:Diet; D015914:Estrogen Replacement Therapy; D004968:Estrogens, Non-Steroidal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D048789:Phytoestrogens; D028321:Plant Preparations; D013025:Glycine max / Q000737:chemistry*
D000975:Antioxidants; D004968:Estrogens, Non-Steroidal; D007529:Isoflavones; D008055:Lipids; D008074:Lipoproteins; D048789:Phytoestrogens; D028321:Plant Preparations